Loss of membranous E-cadherin and β-catenin when taken as one phenotype (E-cad−/β-cat M-) correlated significantly with advanced tumor stage (p = 0.004, OR = 3.2, 95% C.I. = 1.4–7.1), nodal metastasis (p = 0.005, OR = 3.1, 95% C.I. = 1.4–6.9) and late clinical stage (p<0.001, OR = 5.5, 95% C.I. = 2.2–13.4). Here, CDH1 is linked to neoplasm.